People of all races are affected by keloids even though some previous studies demonstrated that keloids
disproportionately occur in specific groups of patients. However, limited studies show that younger patients are
more prone to keloid formation (4). Evidence in India among 1000 patients showed that patients aged 10-30 years
are more affected (4) while another study reported among 120 patients in Nigeria found that young adults are
primarily affected (4). Various studies on keloid prevalence vary according to different countries, with estimates
of 0.09% in England (4), 8.5% in Kenya (4), 0.1% in Japan (4), and 16% in Zaire (4). However, Nigeria reported
an estimated incidence of 1.5 million in 2017 and about 36% of the figure accounted for by familial cases (5).
Evidence from 402 patients living in Ghana, Australia, Canada, and England found that the prevalence of keloids
was higher in the Ghanaian population. Another study reported a high rate of keloids in Chinese descent patients
among 175 patients of Malaysian, Indian, or Chinese descent. A UK-based heterogeneous cohort study examined
excessive scarring among 972 patients which reported prevalence rates of 1.1%, 2.4%, and 0.4% for Asian, Black,
and White patients, respectively (4).
Evidence has shown that surgical excision is the most common therapeutic method. However, there is still a high
recurrence rate of 50% within a year (6). Recently, postoperative adjuvant radiation therapy (RT) has been an
effective method in decreasing the rate of keloid recurrence, especially brachytherapy (6). A randomized trial
showed that patients undergoing surgery and adjuvant radiotherapy had less recurrence than patients undergoing
cryotherapy and intralesional steroid injection and even a better safety profile (7). Previous studies showed that
high-energy electron radiotherapy could provide a better dose distribution than kilovoltage X-rays for controlling
keloids (7). Studies have explored different radiotherapy modalities, doses, and fractionation schedules to optimize
outcomes. For example, electron beam radiation therapy (EBRT) using a dose of 10Gy fractioned for two days
can effectively treat keloid earlobes, and 20Gy fractioned over four days should treat the chest, scapular region,
and suprapubic region (8). Other studies reported a higher dose of 15Gy for earlobes keloids and cartilaginous
part of the auricle keloids with minimal recurrence rates (8).
Despite the effectiveness of radiation therapy for keloid treatment, there is still a paucity of robust data from sub-
Saharan Africa. Few single institutional studies have reported using low-dose RT protocols and recurrence rates
(2). This gap in the literature is particularly observable given the high prevalence of keloid-prone individuals in
this region, such as one conducted in Ibadan, which reported 14.5% recurrence rates among 175 cases with
postoperative RT (9). This five-year retrospective study aims to evaluate the pattern and clinical documentation
of keloid cases treated with radiation therapy in this region.
This study will contribute to the existing body of knowledge and also shape policy decision-making and evidence-
based practice on keloid management in the sub-Saharan context.
METHODOLOGY
The Nigeria Sovereign Investment Authority-Lagos University Teaching Hospital Cancer Center (NSIA-LUTH
Cancer Centre or NLCC) is a specialist cancer treatment facility, the seat of the medical and radiation oncology
department of the teaching hospital. The center provides modern systemic and advanced conformal radiation
therapy services in affiliation with in-hospital surgical services. NLCC is host to Nigeria's largest oncology
workforce in a single center, equipped with 3 Linear Accelerators, modern radiotherapy treatment planning
systems, and the only three-dimensional, high-dose-rate brachytherapy facility in the country, making it the
bestequipped radiation oncology center in the sub-region Africa outside of South Africa. The center’s 10
consultant oncologists all sub-specialized in different cancer sites lead a larger team of medical and radiation
physicists, radiation therapists, oncology nurses, and more. Surgical oncology has been established in the Lagos
University Teaching Hospital for decades with a recent ramping up of surgical oncology investment underway.
This retrospective study utilized data from both physical and electronic medical records at the NSIA-LUTH Cancer
Centre, covering the period from May 2019 to January 2025. A total of 100 patients diagnosed with keloids during
this time were reviewed. 73 keloid patients identified during the study period received radiotherapy (RT). The
diagnosis was based on clinical history and physical examination, while cases managed with surgical excision
were confirmed histologically. Data collected included patient age, gender, ethnicity, body mass index (BMI),
family history of keloids, comorbidities, site of affectation, recurrence, cause of keloid formation, disease duration,
surgical intervention, previous treatments received, and radiation therapy modalities.